In one of these patients, each tumor lineage acquired a genomic alteration in HER2 (ERBB2 amplification, ERBB2L755S mutation), demonstrating convergent evolution of ERBB2 activation following CDK4/6i therapy (Fig. 5A). This evidence concerns the gene CDK4 and neoplasm.